Articles related to FDA

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.

Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.

The FDA’s recent warnings about high-concentration lidocaine in OTC analgesics spotlight a significant health risk, emphasizing the need for healthcare professionals to guide patients in choosing safe and approved pain relief options.

Pemgarda™ emerges as a pivotal development in COVID-19 prophylaxis, particularly for patients with moderate to severe immune compromise, providing a new layer of defense for those less responsive to vaccination.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

The Supreme Court’s deliberations on the Chevron deference and FDA’s drug approval authority underscore a critical juncture for healthcare delivery and regulatory practices, potentially reshaping physician autonomy and patient care standards.